Population | n | CFFCP1 | CFFCP2 | CFFCP3 | CCP2 |
---|---|---|---|---|---|
Rheumatoid arthritis | 322 | 232 (72%) | 251 (78%) | 230 (71.4%) | 238 (73.9%) |
RF+ | 226 | 188 (83.2%) | 199 (88.1%) | 192 (85%) | 199 (88.1%) |
RF-a | 95 | 43 (45.3%) | 52 (54.7%) | 38 (40%) | 39 (41.1%) |
Early | 134 | 102 (76.1%) | 104 (77.6%) | 99 (73.9%) | 99 (73.9%) |
Anti-TNF-α treatment | 78 | 56 (71.8%) | 62 (79.5%) | 61 (78.2%) | 62 (79.5%) |
Healthy blood donors | 307 | 6 (2%) | 6 (2%) | 6 (2%) | 6 (2%) |
Systemic lupus erythematosus | 119 | 11 (9.2%) | 11 (9.2%) | 9 (7.6%) | 9 (7.6%) |
Psoriatic arthritis | 133 | 6 (4.5%) | 13 (9.8%) | 2 (1.5%) | 4 (3%) |
Hepatitis C virus infection | 84 | 12 (14.3%) | 2 (2.4%) | 2 (2.4%) | 1 (1.2%) |